BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, December 22, 2024
See today's BioWorld
Home
» Transition Therapeutics, Novo Deal Worth Up To $56M-Plus
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Transition Therapeutics, Novo Deal Worth Up To $56M-Plus
Nov. 10, 2003
By
Randy Osborne
No Comments
Transition Therapeutics Inc.'s Islet Neogenesis Therapy in Phase I for diabetes bagged the firm a deal potentially worth more than $56 million with Novo Nordisk A/S. (BioWorld Today)
BioWorld
